Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse

NCT03288532 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT03288532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03288532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse
Lead sponsor
University College, London
Phase
Phase 3
Overall status
Recruiting
Start date
July 19, 2018
Completion date
December 1, 2034
Enrollment
1,750 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma